BridgeBio Pharma (BBIO)
(Delayed Data from NSDQ)
$27.09 USD
+1.21 (4.68%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $27.28 +0.19 (0.70%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.09 USD
+1.21 (4.68%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $27.28 +0.19 (0.70%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Zacks News
Amphastar Pharmaceuticals (AMPH) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of -4.95% and 2.51%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 6.42% and 73.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
by Zacks Equity Research
Viatris (VTRS) Q1 numbers fall short of estimates. The company adjusts the annual guidance to reflect the impact of divestitures.
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
by Zacks Equity Research
Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
by Zacks Equity Research
Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
by Zacks Equity Research
Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.05% and 74.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
CHMP Endorses BioMarin's (BMRN) Voxzogo for Use in Infants
by Zacks Equity Research
A final decision study on BioMarin's (BMRN) Voxzogo to treat children above four months with achondroplasia is expected before year's end.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -13.95% and 65.14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: BBIO, ARGX Soar on Study Results, APLS Down on Safety Issues
by Zacks Equity Research
Regulatory and key pipeline updates from BridgeBio (BBIO) and argenx (ARGX) are in focus in the biotech sector.
Here's Why You Should Add Alnylam (ALNY) Stock to Your Portfolio
by Zacks Equity Research
Alnylam's (ALNY) revenues continue to be driven by Amvuttra and Givlaari sales. Its existing collaboration agreement with Regeneron to develop RNAi-based candidates is progressing well.
BridgeBio (BBIO) Up as Heart Drug Meets Primary Goal in Study
by Zacks Equity Research
BridgeBio's (BBIO) shares surge on announcing positive data from a late-stage study evaluating acoramidis for patients with transthyretin amyloid cardiomyopathy.
Company News for Jul 18, 2023
by Zacks Equity Research
Companies In The News Are: F, TSLA, BBIO, PARA.
BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last?
by Zacks Equity Research
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BridgeBio Pharma (BBIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -9.52% and 74.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 1.61% and 8.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last?
by Zacks Equity Research
BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
BridgeBio Pharma (BBIO) Surges 77% YTD: Here's Why
by Zacks Equity Research
Shares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infigratinib in children with achondroplasia, a form of dwarfism.